Search

Your search keyword '"Van Nieuwenhuysen, E."' showing total 237 results

Search Constraints

Start Over You searched for: Author "Van Nieuwenhuysen, E." Remove constraint Author: "Van Nieuwenhuysen, E."
237 results on '"Van Nieuwenhuysen, E."'

Search Results

4. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

8. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

9. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

10. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

11. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

16. 41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer

17. 197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

18. LIO-1: Initiale Phase 2 Erfahrung mit Lucitanib + Nivolumab bei Patientinnen mit persistierendem oder rezidiviertem Zervixkarzinom (NCT04042116; ENGOT-GYN3/AGO/LIO)

19. 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis

20. 615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

21. 732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E

22. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

23. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

24. EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

26. 415 Single-cell map of the dynamic changes underlying platinum-based chemotherapy with or without bevacizumab in high-grade serous tubo-ovarian carcinoma

27. 199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

29. 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

30. Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease.

31. LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

32. LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

34. 51P The development of a predictive model for risk results of the 70-gene signature

35. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

37. 817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial

38. Shared heritability and functional enrichment across six solid cancers.

39. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4).

40. Erratum: Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature communications (2019) 10 1 (431))

41. Shared heritability and functional enrichment across six solid cancers

42. The association between weight at birth and breast cancer risk revisited using Mendelian randomisation

43. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

44. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women

45. Shared heritability and functional enrichment across six solid cancers

46. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

47. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

48. The genetic landscape of 87 ovarian germ cell tumors

49. P78 Robot-assisted management of endometrial cancer in belgium: an analysis of 615 patients by the belgian and luxembourg gynaecological oncology group

50. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Catalog

Books, media, physical & digital resources